Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV

NCT01685814 is registered in ClinicalTrials.gov with Wuerzburg University Hospital as lead sponsor.

NCT NCT01685814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01685814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Lead sponsor
Wuerzburg University Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2012
Completion date
December 31, 2023
Enrollment
406 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

previously untreated symptomatic multiple myeloma